Michelle Dawson posts

Post published on Twitter/X on 13 Jan 2022 04:23

Back to posts Previous post Next post
Twitter/X Clinical trial clinicaltrials.gov Extract quoted in the post External link integrated into the post Autism terms
Open original post

Information about the links integrated into the post

Clinical trial

Institut de Recherches Internationales Servier, ADIR, a Servier Group company (2018). Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.. ClinicalTrials.gov. Institut de Recherches Internationales Servier.

More information
Clinical trial

Institut de Recherches Internationales Servier, ADIR, a Servier Group company (2018). Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder. ClinicalTrials.gov. Institut de Recherches Internationales Servier.

More information

Structured cited links

2 cited resources

Clinical trial Fetched Post clinicaltrials.gov

Institut de Recherches Internationales Servier, ADIR, a Servier Group company (2018). Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.. ClinicalTrials.gov. Institut de Recherches Internationales Servier.

Publication date
4 Oct 2018
Identifier
NCT03715153
Authors
Institut de Recherches Internationales Servier, ADIR, a Servier Group company
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Institut de Recherches Internationales Servier
Metadata source
clinicaltrials.gov

Abstract

The purpose of this study was to evaluate the efficacity and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.

Open source
Clinical trial Fetched Post clinicaltrials.gov

Institut de Recherches Internationales Servier, ADIR, a Servier Group company (2018). Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder. ClinicalTrials.gov. Institut de Recherches Internationales Servier.

Publication date
24 Sep 2018
Identifier
NCT03715166
Authors
Institut de Recherches Internationales Servier, ADIR, a Servier Group company
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Institut de Recherches Internationales Servier
Metadata source
clinicaltrials.gov

Abstract

The purpose of this study was to evaluate the efficacy and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.

Open source